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Abstract 
The potential cardiovascular (CV) disease (CVD) benefits of Omega-3 Polyunsaturated Fatty Acids (OM3) 
have been intensely studied and debated for decades. Initial trials were performed in patients with low 
use of maximal medical therapy for CVD, and reported significant mortality benefits with the use of 1 
gram/day OM3 intervention following myocardial infarction (MI). More recent studies, including cohorts 
of patients receiving modern guideline directed medical therapy for CVD, have often not shown similar 
benefits with OM3 use. We conducted a literature review using PubMed, professional society guidelines, 
specific journal databases including New England Journal of Medicine and Journal of the American 
College of Cardiology from January 1, 2007 to December 31, 2017. References from selected articles 
were also reviewed, as well as key articles outside of the selected time-frame for their important 
findings or historical perspectives.  
Currently, there are no Class I recommendations from the American Heart Association (AHA) for the use 
of OM3, however, considering the safety of this therapy and beneficial findings of some modern studies 
(including patients with current maximal medical therapy for CVD), the AHA has recently expanded their 
list of Class II recommendations, in which treatment with OM3 for CVD benefit is reasonable. This 
review discusses the current state of the evidence, summarizes current professional recommendations, 
and provides recommendations for future research. 
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Abbreviations 
AF = Atrial Fibrillation 
AHA = American Heart Association 
AHRQ = Agency of Healthcare Research and Quality 
ALA = Alpha-linoleic Acid 
ASA = Aspirin 
BP = Blood Pressure 
CHD = Coronary Heart Disease 
CKD = Chronic Kidney Disease 
CV = Cardiovascular 
CVD = Cardiovascular Disease 
DHA = Docosahexaenoic Acid 
DPA = Docosapentaenoic Acid 
DM = Diabetes Mellitus 
EPA = Eicosapentaenoic Acid 
FDA = Food and Drug Administration 
HF = Heart Failure 
HFrEF = Heart Failure with Reduced Ejection Fraction 
LDL-C = Low-density Lipoprotein Cholesterol 
LVSVI = Left Ventricular Systolic Volume Index 
MACE = Major Adverse Cardiovascular Events 
MI = Myocardial Infarction 
OM3 = Omega-3 Polyunsaturated Fatty Acid 
OM6 = Omega-6 Polyunsaturated Fatty Acid 
RCT = Randomized Controlled Trial 
RLP = Remnant Lipoprotein 
SCD = Sudden Cardiac Death 
SDA = Stearidonic Acid 
TG = Triglyceride 
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1. Introduction 
The potential role of Omega-3 polyunsaturated fatty acids (OM3) in reducing cardiovascular (CV) disease 
(CVD) and CVD events has been studied for decades. As early as 1944, Sinclair1 described the rarity of 
coronary heart disease (CHD) in Greenland Eskimos, who consumed a diet high in whale, seal and fish. 
While there are many well-known physiologic benefits of consuming fish or fish oil supplements, and 
multiple CV benefits demonstrated in several studies, there remains much controversy regarding the 
relationship between OM3 and CV health. 
Current guidelines from the American Heart Association (AHA) recommend 2 servings of fatty fish per 
week for the general population,2 and state that it may be reasonable to recommend fish or fish oil 
capsules (1 gram/day OM3) for CVD risk reduction as secondary prevention for patients with CHD and 
other atherosclerotic vascular disease.3 More recently, the AHA concluded that OM3 treatment is 
reasonable for (I) secondary prevention of CHD death, (II) patients with heart failure (HF) with reduced 
ejection fraction (HFrEF), and (III) secondary prevention of CHD in patients with a recent CHD event, 
such as recent myocardial infarction (MI).4 The purpose of this review is to evaluate the current 
evidence regarding OM3 and CV health, explain potential benefits and uses of OM3 and make 
recommendations for future research.  
2. Biochemistry and Sources of OM3 
Biologically relevant families of the polyunsaturated fatty acids are the omega-6 (OM6) and OM3.5 The 
major OM3 include alpha-linolenic acid (ALA, primarily in plants), eicosapentaenoic acid and 
docosahexaenoic acid (EPA and DHA, respectively, both primarily in marine life), and others such as 
stearidonic acid (SDA) and docosapentaenoic acid (DPA) are present in very low amounts in the diet.6 
ALA is found only in trace amounts in green leafy vegetables, but is found in larger quantities in plants 
and seeds as well as plant and seed oils such as flaxseed (also known as linseed), chia, soybean, walnuts 
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and other tree nuts, and olive oil and rapeseed (canola) oils.5,7 Although ALA can be converted to EPA 
with subsequent conversion of EPA to DHA, this conversion is complex and limited.5 In general, humans 
convert < 5% ALA to EPA and even less (0-4%) ALA to DHA.7,8 Some studies suggest possible CV benefits 
of ALA, but the evidence is mixed and inconclusive overall.8 Therefore, plant based OM3 cannot be 
considered a replacement for marine based OM3, specifically EPA and DHA. However, further study for 
the health benefits of ALA is important because of abundant global supply.8  
EPA and DHA enter the food chain through marine phytoplankton or algae, and humans mainly obtain 
these OM3 from consuming fish, particularly oily fish, such as mackerel, trout, salmon, herring, albacore 
tuna and sardines.5,7 Fish do not naturally produce these oils, but obtain them from consuming marine 
microorganisms in their natural diet.7 Therefore, OM3 are typically found in higher levels in wild fish, as 
farmed fish are often grain fed, and the OM3 in fish are not synthesized de novo, but stem from 
unicellular organisms at the base of their natural food chain.9 
“Stealth health” is a concept in which intrinsically enhancing OM3 content of meat from chickens and 
other monogastric animals such as pigs seems readily achievable, and these “stealth health” foods could 
be an ideal mechanism for delivering OM3 without changing dietary habits.10 Also, transgenic animals 
that express the fat-1 gene from the worm Caenorhabditis elegans have been raised, and this gene 
encodes an OM3 fatty acyl desaturase that converts OM3 substrates into OM3; the supplementation 
with meat from these transgenic animals might permit enrichment of mammalian cells with OM3.5 
These methods may one day be used to improve the OM3 status of those whom are deficient, and 
without the need for dietary changes. 
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Figure 1: OM3 Types, Sources and Physiologic Affects 
 
ALA = Alpha Linolenic Acid; DHA = Docosahexaenoic Acid; DPA = Docosapentaenoic Acid; EPA = 
Eicosapentaenoic Acid; LDL-C = Low-density Lipoprotein Cholesterol; OM3 = Omega-3 Polyunsaturated 
Fatty Acid; PCB = Polychlorinated Biphenyl; RLP = Remnant Lipoprotein; SDA = Stearidonic Acid 
3. OM3 Index 
One objective measure of an individual’s OM3 status is the OM3 index, which measures the OM3 
content in red blood cell membranes.11 An OM3 index < 4% has been associated with increased CHD 
risk, particularly sudden cardiac death (SCD), whereas an index > 8% is considered low risk for CHD and 
4-8% is intermediate risk.11 It has been argued that a low OM3 index could serve as a novel CVD risk 
factor, and can also be used to reclassify individuals from intermediate CVD risk to low or high risk 
groups.12 Many previous OM3 intervention trials have yielded neutral results, and it has been proposed 
that incorporating the OM3 index into trial designs  to understand baseline OM3 levels, and treating to a 
target (e.g. 8-11%) will make more efficient trials and treatment possible.12  
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The OMEGA-REMODEL trial suggested that the OM3 index may serve as a useful marker of treatment 
efficacy,13 and it has also been shown that the Global Registry of Acute Coronary Events score had an 
improved c-statistic and correctly reclassified a significant proportion of patients by the inclusion of fatty 
acids.14 We have previously argued that the inadmissibility of memory recall as scientific evidence limits 
the use of many nutritional studies, which may explain why the relation of OM3 in the diet to clinical 
events is looser than the association of measured blood levels of OM3 to clinical events.12,15,16 
 
Figure 2 Potential Use of the OM3 Index 
 
 
4. Physiology 
OM3 have demonstrated the ability to exert beneficial physiologic effects on plasma triglyceride (TG) 
levels, resting heart rate, arrhythmias, atherosclerotic plaque, blood pressure (BP), platelet aggregation 
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and might also improve myocardial filling and efficiency, lower inflammation,  improve vascular function 
and favorably affect autonomic tone.5,8,17-19 With regards to BP reduction, 3 grams/day EPA + DHA has 
been associated with reductions of 4 mmHg and 2 mmHg of systolic and diastolic BP, respectively.11 
Antiplatelet, anti-inflammatory and TG lowering effects of OM3 require relatively higher doses of DHA 
and EPA (3-4 grams/day).7 Further explanation and proposed mechanisms for some of these physiologic 
benefits will be described in the appropriate sections. 
5. Omega 6 
Western diets are low in OM3 but have excessive OM6, such as those in poultry, meat and most 
vegetable oils.5,20 It has been stated that the human body evolved on a diet with an OM6-to-OM3 ratio 
of approximately 1:1, however, the modern ratio in the typical American diet is approximately 14:1 or 
greater.20,21 High OM6:OM3 diet has been said to promote the pathogenesis of many diseases, including 
CVD, cancer and inflammatory/autoimmune diseases, whereas increased levels of OM3 (diets with a 
lower OM6:OM3 ratio) express suppressive pathogenic effects.20 An expert panel for the US military 
unanimously agreed that a military diet with low OM6:OM3 may provide soldiers CV, immunological and 
surgical benefits, and that preloading with OM3 prior to combat may be beneficial and support overall 
resilience.10 
Linoleic acid is the primary dietary OM6 (85-90%), and is converted to arachidonic acid, which is the 
substrate for a variety of pro-inflammatory molecules.22 The inflammatory component of the CHD 
disease process is part of the rationale that reducing OM6 intake can reduce CHD risk. However, the 
AHA concluded that an OM6 intake of at least 5-10% of energy would seem to lower CHD risk, and 
higher amounts may even be more beneficial, and that to reduce OM6 intakes would be more likely to 
increase than to decrease risk for CHD.22 However, meta-analyses of randomized trials and prospective 
observational studies suggest otherwise.23,24 
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6. Landmark Trial: The importance of GISSI-Prevenzione 
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI) – Prevenzione 
(GISSI-P) trial showed that 1 gram/day OM3 decreased the risk of death, nonfatal acute MI and stroke in 
patients surviving recent acute MI.25 However, the study population was receiving very little current 
guideline directed medical treatment, for example, only 5% of patients were receiving statins at 
baseline.26 Multiple later trials, including patients receiving modern optimal medical treatment for CVD, 
have not demonstrated as favorable results as those of GISSI-P, and it is therefore possible that OM3 has 
little benefit in the presence of maximal medical treatment for CVD.4  
This landmark trial used an OM3 dose of 1 gram/day, which many subsequent intervention trials have 
followed. Multiple studies have demonstrated favorable CV effects using higher doses of OM3 
supplementation (e.g. 4 grams/day).13,27,28 It has been reported that the TG level is a significant 
independent risk factor for CHD,11 and even though it is well established that OM3 lower TG levels, 
doses > 1.5 grams/day are typically needed for a clinically meaningful change.29 Therefore, the 1 
gram/day OM3 intervention in GISSI-P, and many subsequent studies, may perhaps be an insufficient 
dose to yield significant CVD benefits. Ongoing studies with higher dose interventions are currently 
underway, such as REDUCE-IT and STRENGTH.  
Baseline OM3 levels are determined by diet, which is inevitably influenced by geographic location. GISSI-
P and other important studies, such as JELIS, were conducted in Italy and other regions where baseline 
OM3 intake is significantly higher than that of North American populations. Therefore, the higher 
baseline levels of OM3 in these populations which demonstrated CVD benefits with an intervention of 1 
gram/day OM3, may require significantly higher OM3 doses in North American populations,30 with 
known OM3 deficiency, to obtain similar total OM3 levels and achieve similar benefit.  
7. Recent Update from the AHA Science Advisory 
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In 2002, the AHA published a scientific statement recommending that patients with documented CHD 
consume ~1 gram/day EPA + DHA, preferably from oily fish, based on 2 large randomized controlled 
trials (RCTs).4 An updated statement was released in 2017 (Table 1), and the AHA concluded that the 
available evidence does not support the use of OM3 supplementation in the general population who are 
not at high CVD risk, and there was a lack of consensus about the benefits for those at high CVD risk. The 
AHA continues to suggest that OM3 supplementation is reasonable for secondary prevention of CHD in 
patients with a recent CHD event, such as MI, and added a new recommendation for patients with 
HFrEF, in whom OM3 supplementation may be considered.4 
Table 1: 2017 Updated AHA Science Advisory regarding OM3 supplementation 
Cohort Evidence Recommendation Comments 
Primary prevention of 
CHD 
No RCTs exclusively 
studying primary 
prevention of CHD 
No Recommendation  
Prevention of CVD 
mortality in DM or 
prediabetes 
Overall, the current 
evidence from RCTs 
suggests no benefit of 
OM3 among patients 
with or at risk for DM to 
prevent CVD 
Class III: No benefit  
Prevention of CHD in 
patients with high CVD 
risk 
2/3 trials showed no 
benefit from OM3 
supplementation on 
clinical CHD 
Majority:  
Class III: No benefit 
 
Minority:  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
JELIS showed reduced 
risk of the composite 
outcome with OM3 use, 
but little evidence of risk 
reduction in hard 
endpoints (non-fatal MI, 
CHD death) 
Class IIb: Treatment is 
reasonable 
Secondary prevention 
of CHD and SCD in CHD 
patients 
OM3 supplements may 
reduce CHD death, 
possibly through a 
reduction in ischemia-
induced SCD, among 
patients with prior CHD, 
but the treatment does 
not reduce the incidence 
of recurrent nonfatal MI 
Majority: 
Class IIa: Treatment is 
reasonable 
 
Minority:  
Class IIb: Treatment is 
reasonable 
 
Primary prevention of 
Stroke 
Overall, there is no 
proven benefit of OM3 
to reduce risk of stroke 
among patients without 
a history of stroke 
Class III: No benefit Stroke was not a 
primary outcome in 
any RCT, and there is 
little evidence of 
reduction in stroke 
events with OM3 
supplements from 
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meta-analyses 
Secondary prevention 
of Stroke 
Overall, there is no 
evidence of OM3 
supplementation to 
reduce risk of stroke or 
other CVDs in patients 
with prior stroke 
No recommendation Post hoc analysis of 
JELIS patients with a 
history of stroke had 
6.8% stroke 
recurrence who 
received EPA vs 10.5% 
in controls, for risk 
reduction of recurrent 
stroke of 20% (RR 
0.80; 95% CI 0.64-
0.997), number 
needed to treat 27 
 
These results should 
be considered for 
hypothesis generating 
Primary prevention of 
HF 
No RCTs to date No recommendation  
Secondary prevention 
of outcomes in patients 
with HF 
Based on a single, large 
RCT, in which 91% pts 
had EF < 40% 
 
Class IIa:  
Treatment is 
reasonable among 
patients with HFrEF 
OM3 may reduce HF-
related 
hospitalizations and 
death in patients with 
HFrEF 
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More RCTs are 
needed among 
patients with HFpEF 
Primary prevention of 
AF 
No data from large RCTs No recommendation  
Secondary prevention 
of AF in patients with 
prior AF 
Overall, high-quality 
evidence from multiple 
RCTs does not support 
OM3 supplementation 
to prevent recurrent AF 
Class III: No benefit  
AF after cardiac surgery 6 RCTs did not find OM3 
reduction of 
postoperative AF 
Class III: No benefit  
Comment: The doses of OM3 (~1000mg) used in the studies in this scientific statement (other than 
JELIS, 1800mg) are generally too low to meaningfully lower TG levels 
 
AF = Atrial Fibrillation; CHD = Coronary Heart Disease; CVD = Cardiovascular Disease; DM = Diabetes 
Mellitus; EF = Ejection Fraction; EPA = Eicosapentaenoic Acid; HF = Heart Failure; HFpEF = Heart 
Failure with Preserved Ejection Fraction; HFrEF = Heart Failure with Reduced Ejection Fraction; MI = 
Myocardial Infarction; OM3 = Omega-3 Polyunsaturated Fatty Acid; RCT = Randomized Controlled 
Trial; RR = Relative Risk; SCD = Sudden Cardiac Death 
 
8. AHRQ Evidence Update 
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The Agency of Healthcare Research and Quality (AHRQ) performed an evidence review of the 
relationship between OM3 and CVD in 2004, with an update in 2016 (Table 2).6 Overall, the effects of 
OM3 on intermediate CVD outcomes remain largely unchanged. The current National Institute for 
Health and Care Excellence recommendations for CVD prevention concluded that the evidence does not 
support the use of OM3 supplements for people being treated for primary or secondary prevention, 
people with chronic kidney disease (CKD) or diabetes mellitus (DM).31 It was also concluded that there is 
moderate strength of evidence that marine oil supplementation lowers risk of major adverse CVD events 
(MACE) and CVD death, and low strength of evidence that higher marine oil intake is associated with 
lower risk of CHD and HF.6 
 
Table 2 – Updated AHRQ evidence review summary 
Level of evidence Population Outcome 
High strength Various Marine oils lower TG concentrations 
and raise HDL and LDL levels 
High strength Various No effect of marine oils on risk of major 
adverse CV events, all-cause death, 
SCD, revascularization and BP 
Moderate strength Various No effect of marine oils on risk of AF 
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Low strength Various No effect of marine oils on risk of CVD 
death, coronary disease death, total 
coronary disease, MI, angina pectoris, 
CHF, total stroke and hemorrhagic 
stroke 
Insufficient evidence Various Effect of OM3 and most clinical 
intermediate outcomes 
Observational evidence Patients without 
known CVD 
Evidence of no association for MACE, 
CVD death, total stroke death, incident 
coronary disease, total stroke, ischemic 
stroke, hemorrhagic stroke, AF and CHF 
Strong RCT evidence Patients without 
known CVD 
No effect for BP, MAP, LDL and HDL but 
significantly lowers TG concentrations 
Strong RCT evidence Patients with increased 
risk for CVD 
No effect on MACE, all-cause death, BP, 
LDL, HDL but significant lowering of TG 
concentrations 
RCT evidence Patients with known 
CVD 
No effect for MACE, CHD death, all-
cause death, MI, revascularization, 
total stroke, SCD, AF and CHF 
 
Strong RCT evidence of no effect on BP 
and LDL but protective effect for HDL 
and TG concentrations 
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AF = Atrial Fibrillation; BP = Blood Pressure; CV = Cardiovascular; CVD = Cardiovascular Disease; CHF 
= Congestive Heart Failure; HDL = High-density Lipoprotein; LDL = Low-density Lipoprotein; MACE = 
Major Adverse Cardiovascular Events; MAP = Mean Arterial Pressure; MI = Myocardial Infarction; 
RCT = Randomized Controlled Trial; SCD = Sudden Cardiac Death; TG = Triglyceride 
9. Lipid profile and Atherosclerosis 
TG elevation is an independent risk factor for CVD events,11,32 and it is well established that OM3 
reduces TG levels.29 Generally, there is no significant improvement in low-density lipoprotein cholesterol 
(LDL-C) levels with fish oil therapy, especially in patients with high TG levels, who often notice increases 
between 5% and 50%.7 However, this OM3-enriched LDL develops a molecular structure described as 
“larger and fluffier” (or pattern A LDL-C), which is potentially less atherogenic than the smaller, denser 
particles (pattern B LDL-C).7 
OM3 may also reduce atherosclerosis and CVD via reduction of Remnant lipoprotein (RLP) levels.18 RLP 
exerts atherogenic effects, is considered an important risk factor for CVD, has been suggested in the 
pathogenesis of SCD and re-stensosis following coronary angioplasty,18 and has been reported to be a 
likely causal factor for CHD.33 OM3 may consequently prevent plaque development and contribute to 
plaque stabilization.18 OM3 could over many years or at higher doses alter chronic atherogenesis and/or 
acute plaque rupture, lowering nonfatal coronary syndromes.8 
9.1 OM3 Formulations 
EPA and DHA may be present in an ethyl ester form, TG form, as a free fatty acid or as phospholipids.34 It 
has been suggested that the form consumed may affect bioavailability, but ultimately that long term 
daily administration resulted in similar plasma and RBC levels of EPA + DHA, irrespective of 
formulation.35 Lovaza is an OM3 ethyl ester formulation approved by the US Food and Drug 
Administration (FDA) at a dose of 4 grams/day for the treatment of very high TG levels (≥500 mg/dl).7 
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Icosapent ethyl (Vascepa) is a high-purity EPA formulation containing >96% EPA ethyl ester, does not 
contain DHA, and is approved in the US to lower TG levels in adult patients with severe (≥ 500mg/dl) 
hypertriglyceridemia.36 The ongoing REDUCE-IT trial has randomized patients at 470 centers worldwide, 
and aims to reveal if treatment for moderate TG elevation decreases CVD events, particularly among 
patients already receiving statin therapy. 
10. Coronary Heart Disease 
25 studies with 280,000 patients showed an inverse association between fish consumption and 
morbidity or mortality from CHD.5 Alexander et al.37 performed a large meta-analysis (n = 93,000 
subjects in RCTs and n = 732,000 in prospective cohort studies) regarding the effects of EPA + DHA on 
CHD and CHD risk. EPA + DHA reduced CHD risk among subjects with TG >150 mg/dl or LDL-C > 130 
mg/dl in RCTs, but not among those with normal TG levels or LDL-C < 130 mg/dl.11 The authors 
concluded that EPA + DHA may be associated with reducing CHD risk, with a greater observed benefit 
among higher risk populations in RCTs, and higher dose (> 1gram/day EPA + DHA) had stronger impact.37 
Information from prospective cohort studies is important, considering that greater than 50% of CVD 
deaths occur among individuals without diagnosed CVD, and these studies are able to evaluate 
populations that are healthy at baseline.38 This is a strength not found in the AHA 2017 update regarding 
OM3 and CVD, as the update only considered RCTs in its analysis. Alexander et al.37 concluded that 
although not significant, a 6% reduced risk of any CHD event was observed among RCTs, which was 
supported by a statistically significant 18% reduced risk of CHD among prospective cohort studies. 
Another meta-analysis of 14 RCTs with n > 32,000 found that OM3 use in patients with CHD was not 
associated with a protective effect on MACE, while there seemed to be beneficial effects in reducing 
death from cardiac causes, SCD and all-cause mortality.39 A 22 year study of > 20,000 patients found that 
OM3 supplementation was associated with a lower hazard of CHD mortality.40 The JELIS trial in Japan 
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used 1800 mg/day EPA with statin therapy or statin therapy alone, finding a relative risk reduction with 
any major CHD event of 19% (p=0.011).41 Patients in this study with a history of CHD in the EPA group 
had significantly lower incidence of major CHD events, while patients without a history of CHD did not.41 
A recent meta-analysis of >77,000 high risk individuals found that OM3 had no significant association 
with fatal or nonfatal CHD or any MACE.42 
10.1 Antiplatelet therapy and OM3 
The biologic response to aspirin (ASA) is not uniform,43 and clopidogrel has a much higher incidence of 
low responsiveness.44 The OMEGA-PCI study intervention of 1 gram/day OM3 showed P2Y12 reactivity 
index was significantly lower by 22.2% after 1 month with OM3 compared to placebo (p=0.02).44 The 
authors concluded that the addition of OM3 to dual antiplatelet therapy significantly potentiates 
platelet response to clopidogrel following percutaneous coronary intervention. Triple antiplatelet 
therapy with the addition of cilostazol has also been reported to improve the biological effects of 
clopidogrel.44  
Another study by Lev et al.43 concluded that treatment of ASA resistance by adding OM3 or increasing 
ASA dose (325 mg/day) seems to improve responsiveness to ASA and effectively reduces platelet 
activity. However, it has been shown that increasing ASA dose results in no difference in clinical efficacy 
for prevention of vascular events, but increased gastrointestinal side effects and bleeding.45 Therefore, 
although antiplatelet agent resistance may potentially be reduced by the use of OM3, increasing ASA 
dosage or triple antiplatelet therapy, OM3 supplementation may be the safer option. It has previously 
been concluded that there was no increased risk of clinically significant bleeding with OM3 doses up to 7 
grams/day DHA + EPA, even when combined with antiplatelet therapy or warfarin.46 
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10.2 Recommendations 
The majority of authors from the AHA concluded that for patients at high CVD risk, treatment with OM3 
is not indicated, while a minority concluded that treatment is reasonable.4 OM3 supplements do not 
seem to reduce the incidence of recurrent nonfatal MI, however, the AHA concluded that even a 
potential reduction in CHD death of 10% would justify the use of a relatively safe therapy.4 
11. Post Myocardial Infarction 
Greene et al.25 studied the use of 1 gram/day OM3 and found that it was independently associated with 
decreased risk of all-cause mortality and acute MI, in addition to a robust reduction in recurrent acute 
MI through 12 month follow-up. The OMEGA trial in Germany, in patients with a high baseline (85-95%) 
of guideline directed treatment, use of 460 mg EPA + 380 mg DHA for one year initiated 3-14 days after 
acute MI was associated with low arrhythmic (0.7%) and total mortality (3.7%) event rates in the 
placebo group, and this trial showed no benefit of EPA + DHA.7 Although probably underpowered, these 
results suggest that OM3 may not provide additional short-term protection in patients receiving modern 
post-MI therapy.7 
The Alpha Omega trial tested the hypothesis that low doses of EPA + DHA (400 mg/day), ALA (2 
grams/day), or both reduce the risk of CVD events among patients who have had a MI.26 This trial 
studied patients with a history of MI up to 10 years prior to randomization and found that OM3 
compared to placebo had no effect on MACE, although post hoc analysis found reductions of 
approximately 50% on rates of fatal CHD and arrhythmia-related events.26 The average daily OM3 intake 
in the intervention arm was <400mg/day,25 which may also suggest that higher doses of OM3 may be 
needed for CVD benefits.  
The OMEGA-REMODEL found that 6 months of high dose OM3 (4 grams/day) following acute MI had 
significant reduction of left ventricular systolic volume index (LVSVI) (-5.8%, p=0.017) and non-infarct 
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myocardial fibrosis (-5.6%, p=0.026) using Lovaza compared with placebo beyond current guideline-
based standard of care.13 Many studies reported that improvement of LVSVI during infarct 
convalescence remains the strongest favorable risk predictor, parallels reduction of post-MI mortality 
rates, and is part of the pathway of therapies that reduce mortality, SCD and HF.13 Changes of LVSVI 
from OM3 treatment started 2-4 weeks post MI were only modest, suggesting that earlier initiation of 
OM3 following MI may have resulted in more significant benefit.13  
11.1 Recommendation 
According to the 2017 updated AHA scientific statement, the recommendation for patients with CHD, 
such as recent MI, remains unchanged from 2002: treatment with OM3 in these patients is reasonable.4 
Certainly, further study is required.  
12. Risk for cardiac death 
The benefits of OM3 seem most consistent for CHD mortality and SCD.8 Higher OM3 levels may alter the 
risk for fatal and non-fatal CVD events through several pathways, including anti-arrhythmic effects 
(particularly arrhythmias related to MI), effects related to cardiac structure and function (fibrosis, 
myocardial oxygen demand), endothelial and autonomic function (vascular resistance and heart rate), 
thrombosis, BP, inflammation and lipoprotein metabolism.8 The final common pathway for most cardiac 
death is arrhythmia,8 and several different mechanisms for reduced arrhythmogenicity and SCD have 
been proposed.  
12.1 Anti-arrhythmic properties 
Animal experiments suggest that OM3 directly influence atrial and ventricular myocyte 
electrophysiology, potentially mediated by effects on membrane ion channels or cell-cell connexins.8 
OM3 cause steric interference with sodium, potassium and calcium channels; a blocking mechanism that 
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is distinct from that of other known antiarrhythmic agents.5 OM3 may prolong the relative refractory 
period by modulating L-type calcium channels, preventing calcium overload during ischemic insult,18 and 
in vitro and animal models show that OM3 stabilize partially depolarized ischemic myocytes, reducing 
susceptibility to ventricular arrhythmias.8 
12.2 Evidence 
Maki et al.29 performed a meta-analysis (n = 71,899) reviewing OM3 supplementation and risk for CVD 
death, finding 8% lower risk with OM3 versus control. The authors also argued that OM3 
supplementation has low risk associated with its use, and therefore even a modest benefit is clinically 
meaningful. 3 RCTs evaluating the effects of OM3 on recurrent ventricular tachycardia or fibrillation in 
patients with implantable cardioverter-defibrillator devices were evaluated, one showing 31% reduction 
in recurrence of these arrhythmias (p = 0.03%), whereas the other 2 trials showed no statistically 
significant effects.8 Overall, these studies are limited by small sizes and brief treatment. The Singapore 
Chinese health study recruited 60,298 Chinese adults and found that high intake of both marine and 
plant OM3 are independently associated with reduced risk of CVD mortality.19 Mozaffarian et al.47 
performed a trial in patients age 75 ±5 years without CHD, stroke or HF, and found that OM3 levels were 
associated with lower total mortality, fewer CVD deaths, and particularly fewer arrhythmic CHD deaths, 
with nearly 50% lower risk across quintiles.  
12.3 Recommendations 
According to the AHA, the cumulative findings from RCTs suggest that OM3 supplements may reduce 
CHD death, possibly through a reduction in ischemia-induced SCD, among patients with prior CHD, but 
the treatment does not reduce the incidence of recurrent nonfatal MI.4 Given that the benefit of OM3 
use likely outweigh any risk of treatment, the majority of co-authors concluded that treatment with 
OM3 is reasonable for secondary prevention of CHD death.4 
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13. Atrial Fibrillation 
Considering that rhythm control strategies for Atrial Fibrillation (AF) either involve antiarrhythmic drug 
treatment (with modest protection against AF recurrence and non-negligible side effects) or ablation 
(limited by availability and high cost), safe and inexpensive alternatives certainly need to be explored.48 
The FORWARD trial evaluated the efficacy of 1 gram/day OM3 supplementation for the prevention of 
recurrent AF, finding no significant differences between study groups.49 However, this study was 
stopped early and was underpowered, with 63% of patients receiving prophylaxis with amiodarone at 
inclusion, and did not use trans-telephonic monitoring for identification of recurrent AF.49  
The AFFORD trial used a higher dose of OM3 (4 grams/day) and monitored AF recurrence via trans-
telephonic monitoring, finding no reduction in AF recurrence up to 16 months in patients not receiving 
antiarrhythmic therapy.48 The AFFORD authors believe that their results provide conclusive evidence 
that fish oil has no role in rhythm-control management of patients with paroxysmal or persistent AF. 
13.1 Postoperative AF 
Mozaffarian and colleagues,50 after publishing a trial showing that perioperative fish oil did not reduce 
post-operative AF, performed a meta-analysis on the subject. The authors concluded that there was 
convincing evidence that short-term OM3 use does not appreciably reduce post-operative AF, regardless 
of the type of cardiac surgery.50 
13.2 Recommendations 
There is currently no compelling evidence for OM3 use in the prevention or treatment of AF. The AHA 
reports that there is no data from large RCTs regarding effects of OM3 for primary prevention of AF.4 
Regarding secondary prevention of AF, the AHA concluded that overall, high-quality evidence from 
multiple RCTs does not support OM3 supplementation.4 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
14. Heart Failure 
In a small 18-week pilot study of 14 patients with class III-IV HF randomized to 5.1 grams/day of EPA and 
DHA, we showed marked improvements in inflammatory cytokines and percent body fat in advanced 
HF, suggesting that fish oil may be beneficial in decreasing inflammation and cachexia in advanced HF.51 
Diets rich in unsaturated fatty acids have been associated with improved cardiorespiratory fitness, 
diastolic function and body composition in obese patients with HF,52 and a meta-analysis of 7 
prospective studies found a lower risk of HF with intake of marine OM3.53 
The GISSI-HF trial suggested that 1 gram/day OM3 showed lower death from any cause (27% vs 29%) 
and hospitalizations for CV reasons (57% vs 59%) in the OM3 group vs placebo, respectively.41 This study 
suggested a number needed to treat of 56 for 3.9 years to avoid one death or 44 needed to treat to 
avoid one event like death or admission to hospital.54 This trial showed a reduction of total mortality by 
8% (p = 0.009), accompanied by significant improvements in left ventricular ejection fraction, when 
given in addition to maximal modern drug therapies.8 
There seems to be a “blunting effect”, in which the benefit of OM3 is reduced by maximal medical 
management, which may not be as significant or as prevalent in the HF population, considering these 
findings. Also, considering that 1 gram/day may be an insufficient dose, more studies using higher doses 
of OM3 in HF patients will be particularly helpful. However, the potential impact of this therapy over 
maximal guideline directed therapy is still questionable, considering that although >90% of patients 
were taking either an angiotensin converting enzyme inhibitor or aldosterone receptor blocker, only 
approximately 65% of patients were taking a beta blocker in GISSI-HF.54 
14.1 Heart transplant 
Hypertension is a common complication in cyclosporine treatment, present in 60-100% of heart 
transplant patients,28 and studies suggest that OM3 can reduce heart rate, mean arterial pressure, 
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systemic vascular resistance, left ventricular hypertrophy and improve diastolic function in transplant 
patients with cyclosporine-induced hypertension.55 In a small study (n=28), Andreassen et al.28 
randomized heart transplant patients to 4 grams/day OM3 vs corn oil placebo from the 4th post-
operative day, finding after 6 months that systolic BP decreased 2 ± 4 mmHg in the treatment group and 
increased by 17 ± 4 mmHg in the placebo group (p < 0.01), whereas diastolic BP increased by 10 ± 3 and 
21 ± 2 in the treatment and placebo groups, respectively (p = 0.01). The authors concluded that post-
operative daily OM3 supplementation of 4 grams/day in heart transplant patients is effective as 
hypertension prophylaxis. Ventura and colleagues55 have also demonstrated BP and systemic vascular 
resistance reductions using OM3 3 grams/day in orthotopic cardiac transplant patients receiving 
cyclosporine therapy, also suggesting that OM3 can be used as an adjuvant for HTN treatment in 
cyclosporine-treated cardiac transplant patients. 
14.2 Recommendations 
It appears that the beneficial effects of OM3 in patients with HF and heart transplant are promising. We 
agree with Fonarow’s56 assertion that OM3 supplementation should join the short list of evidence-based 
life-prolonging therapy for HF. To date, no published RCTs have assessed the effect of OM3 on primary 
prevention of HF.4 Based on the results of GISSI-HF, a single, large RCT of HF patients (91% having HFrEF 
and Ejection Fraction <40%), OM3 supplementation reduced risk of total mortality by 9% and risk of CVD 
related hospitalizations or death by 8%,54 leading to a new recommendation from the AHA that 
treatment with OM3 is reasonable among patients with HFrEF.4 
15. Ischemic Stroke 
Although meta-analyses suggest that fish consumption reduces the risk of ischemic stroke, stroke 
incidence has not been significantly affected in fish oil trials, and there are currently not enough 
appropriately powered RCTs to evaluate the OM3 effects on stroke.8 There are no RCTs regarding OM3 
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effect on stroke or other CVD events among patients with a history of stroke, although post hoc analysis 
of JELIS patients who had a history of stroke had reduced recurrent stroke in the OM3 group.4 Overall, 
there is no evidence of OM3 supplementation to reduce the risk of recurrent stroke or other CVD in 
patients with prior stroke.4 
16. Peripheral Artery Disease 
With regard to peripheral arterial disease, there is very little evidence to produce recommendations for 
OM3 use. One meta-analysis of 5 trials (n = 396), all of which with unclear or high risk of bias, with most 
of the study population (n = 213) in a single trial, found no evidence of a protective association of OM3 
supplements on MACE or other serious clinical outcomes.57 There was no evidence to suggest a 
protective association of OM3 with MI, CVD death, angina, stroke, amputation, revascularization, pain-
free walking distance or quality of life.57 
17. Primary prevention of CVD 
There may only be one RCT of OM3 use for the primary prevention of CVD.58 The Diet and Omega-3 
Intervention Trial (DOIT), was a placebo-controlled trial in 563 elderly men at high-risk of CVD.  OM3 (2.4 
grams/day) caused a borderline significant 47% reduction in all-cause mortality (p=0.063). There is no 
proven benefit for primary prevention of stroke, HF or AF. The ongoing VITAL trial will test the efficacy 
of Vitamin D (2000 IU/d) and OM3 (1 gram/day) for prevention of cancer and CVD in a multiethnic 
primary prevention population of 25,875 patients.59 The National Institute of Health concluded that the 
evidence does not support the use of OM3 supplements for people being treated for primary or 
secondary prevention, people with CKD or DM.6 However, as reviewed above, this therapy appears to be 
of at least modest benefit in patients with elevated TGs and /or LDL-C at least in some meta-analyses, 
and considering the low cost and side effect profile, could be considered for these populations. 
18. Secondary prevention of CVD 
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The AHA has concluded that “treatment is reasonable” for (1) secondary prevention of CHD and SCD 
among patients with prevalent CHD; and (2) secondary prevention of adverse outcomes in patients with 
HF.4 Due to a lack of RCTs, there is no recommendation for secondary prevention of stroke, and high 
quality evidence from multiple RCTs does not support OM3 for prevention of recurrent AF.4  
19. Safety and Sustainability 
19.1 Contaminants and side effects 
Due to the concern for methyl mercury in diets high in fish consumption, the FDA advised children and 
pregnant or nursing women to consume a minimum of two to three servings, or eight to 12 ounces, of 
low-mercury fish every week, and to specifically avoid fish with potentially high mercury content, such 
as swordfish, tile fish, king mackerel and shark.7 Nevertheless, a study of almost 12,000 British women 
found that women who exceeded the FDA recommendation for fish intake actually had offspring with 
better cognitive and behavioral development than women who consumed less fish during pregnancy.60 
For the general population of adults, risk-benefit analyses conclude that the health benefits of modest 
fish consumption significantly outweigh the potential risks.5,8  
The most commonly consumed dietary sources of marine OM3 include salmon, sardines, trout, oysters 
and herring, which are quite low in mercury content.61 Because mercury is water soluble and protein 
bound, it is present in the muscle of fish but not in the oil, and therefore, fish oil supplements contain 
negligible amounts of or no mercury.7,8 Fish oil supplements also contain low absolute quantities of 
dioxins and polychlorinated biphenyls.8 The FDA concluded that marine OM3 doses of up to 3 grams/day 
are “generally recognized as safe”,62 and the most common adverse effects of OM3 supplementation 
are nausea, gastrointestinal upset and “fishy” burp.7 The fishy taste or eructation may be minimized by 
taking the capsule frozen, switching to a different formulation with a low oxidation profile, or taking 
with meals or at a different time of day.8 
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19.2 Malignancy 
Articles in popular media have suggested that OM3 ingestion may increase the risk of prostate cancer 
and many have advised against the use of supplemental fish oil.63 However, a regular high intake of fish 
has been linked to a marked increase in survival in prostate and other cancer patients, and Japan has a 
many-fold lower prostate mortality rate than the US, despite Japanese men typically consuming 
approximately 8 times more fish than American men.63 The American Cancer Society also reports that 
most men diagnosed with prostate cancer do not die from prostate cancer,64,65 therefore, considering 
that CVD is a leading cause of morbidity and mortality, a therapy that can potentially reduce CVD risk 
such as OM3 therapy should not be discredited without substantial evidence of risks. With regards to 
cancer in general, many large randomized trials of fish oil supplementation have never found an 
increase in cancer incidence or mortality in those receiving OM3 supplements.63,66 Also, a recent major 
study suggested that a diet relatively high in OM3 compared with OM6 was associated with lower risks 
of several adenocarcinomas, and that DHA specifically may serve as an important adjunct to improving 
the efficacy of several chemotherapeutic agents.9 Other studies have shown benefits with regards to 
maintaining weight and muscle mass, potential to chemosensitise tumors and improve quality of life in 
patients with various cancers.67-69 
19.3 Sustainability 
The supply of seafood from global capture fisheries has plateaued and is unlikely to supply adequate 
amounts of additional seafood to the world’s growing population.70 Global fish stocks have declined 
rapidly over the past 50 years; populations of some commercially popular fish species have collapsed to 
only 10% of their historic maximum, with over 100 confirmed extinctions of marine species.71 The catch 
from wild fish stocks is generally considered to be at or near the biological maximum, with 
approximately 90% of the fish stocks globally rated as fully or overexploited.70 
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Some researchers have argued that wild fish populations are collapsing and blanket recommendations 
to increase OM3 from marine sources will only exacerbate this problem.71 Although predictions from 
experts stating that worldwide fish stocks could be depleted within 40 years at the current harvest rate 
have been severely criticized and possibly overly pessimistic, the pressure on fish stocks is likely to 
increase with recommendations for increased consumption of fish and fish oil.71 According to some 
authors, it is clear that fish and vegetable oil sources will not be sufficient to meet the future needs of 
the world population.72  
Production of single-cell oil (yeast or microalgae) comes as a sustainable alternative with less 
environmental impact.72 However, these alternatives have significant limitations; plants rich in SDA are 
expensive, metabolic engineering is unfavorably accepted by consumers in many countries, cultivation 
of microalgae is very expensive, and Antarctic Krill harvest must be restricted.73 There are significant 
ecological impacts that will likely result from an initiative to increase fish or fish oil consumption for the 
general population. Alternative sources of OM3 such as those from single-cell oils or “stealth health” 
methods mentioned previously need to be further explored in an attempt to satisfy OM3 intake 
recommendations and lessen the burden of commercial fishing on marine ecosystems in order to 
achieve sustainability. 
Table 3 Patients who may benefit from OM3 
Those not meeting recommended dietary fish intake 
CHD or other ASCVD 
Secondary prevention of CHD death or SCD 
Recent CHD event (e.g. post-MI) 
Following PCI 
HFrEF 
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Heart Transplant 
Aspirin Resistance 
Clopidogrel Resistance 
Hypertriglyceridemia (>150 mg/dl) 
High LDL-C (>130 mg/dl) 
Hypertension 
ASCVD = Atherosclerotic Cardiovascular Disease; CHD = Coronary Heart Disease; HFrEF = Heart Failure 
with Reduced Ejection Fraction; LDL-C = Low-density Lipoprotein Cholesterol; MI = Myocardial 
Infarction; PCI = Percutaneous Coronary Intervention; SCD = Sudden Cardiac Death 
 
20 Conclusion 
While dietary intake of oily fish is currently recommended, fish oil supplementation is certainly a safe 
and reasonable alternative. There is no convincing evidence that OM3 increases risk of malignancy, and 
may in fact be protective. While OM6 has been associated with increased inflammation and 
pathogenesis of various disease processes, the AHA currently recommends an OM6 intake of at least 5-
10% of total energy, which would seem to lower CHD risk. 
Favorable CV effects found in older studies, such as GISSI-P, have been difficult to replicate in modern 
trials, likely due to the use of modern maximal medical therapy for CVD. Also, the use of 1 gram/day 
OM3 intervention in early landmark trials is often still used in current trials, despite possibly being an 
insufficient dose. We recommend that future research (I) focus on higher dose interventions using OM3 
(II) in patients already receiving maximal medical therapy for CVD, (III) incorporate an objective measure 
of OM3 status, such as the OM3 index, to assess treatment efficacy and aid in the comparison of future 
trials, and (IV) implement early intervention following events such as MI or cardiac transplantation. 
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OM3 promote a favorable lipid profile that reduces levels of RLP, possibly reducing atherogenicity of 
LDL-C. OM3 may consequently prevent plaque development and contribute to plaque stabilization, and 
therefore may be beneficial when added to standard lipid-lowering therapy. We look forward to the 
results of the ongoing REDUCE-IT trial.  
Resistance to antiplatelet agents is associated with increased risk of CHD events, and although this 
resistance may be reduced by: (I) triple therapy with ASA + clopidogrel + cilostazol, (II) high-dose ASA 
use, or (III) OM3 supplementation, the use of OM3 may be the safer option. OM3 does not seem to 
increase risk of bleeding. 
The best evidence for the use of OM3 and CV health is for CHD mortality, SCD, post-MI and HFrEF. The 
AHA now recommends treatment for patients with HFrEF with OM3 to reduce mortality and 
hospitalizations.4 Some of these studies have shown favorable results with higher OM3 dosage (4 
grams/day) and treatment early following MI or heart transplant, despite being used in patients 
receiving optimal medical therapy. OM3 use is reasonable for patients with CHD, such as recent MI, 
according to the AHA.4 
There is insufficient evidence for recommendations regarding ischemic stroke and peripheral arterial 
disease, although there has been some evidence of benefit for secondary prevention of ischemic stroke 
with the use of OM3 in the JELIS trial. Currently, OM3 appear to play no role in the prevention of new or 
recurrent AF. 
According to the AHA, the evidence does not support the use of OM3 supplementation in the general 
population who are not at high CVD risk, and there was a lack of consensus about the treatment of 
those at high risk.4 Treatment is also considered reasonable for secondary prevention of CHD death, and 
does not appear to have any role in treatment or prevention of AF. The AHA has no class I 
recommendations for the use of OM3, and our findings indicate that there is currently insufficient 
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evidence for OM3 use in the primary prevention of CVD in general, which is in agreement with 
recommendations from the AHA and National Institute of Health.4,6  
A recurring argument for proponents of OM3 use is that even modest reduced risk of CVD or CV events 
should encourage the use of a largely innocuous therapy. Although the majority of authors from the 
AHA concluded that treatment with OM3 is not indicated for patients at high CVD risk, the AHA 
concluded that a potential reduction of CHD death by 10% would justify the use of OM3.4 The AHA 
acknowledges that the lack of evidence of benefit differs from evidence of a lack of effect,4 however, the 
magnitude of benefit from OM3 for CV health remains largely undetermined. However, in patients with 
even moderately elevated LDL-C and /or TGs, this therapy could be strongly considered based on 
potential benefits and low cost and toxicity. 
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